Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
Lenvatinib: a Receptor Tyrosine Kinase Inhibitor
MOA Magnifiers
Mechanism of Action Magnifier – 2016 Desk Reference
Read More
Abemaciclib (LY2835219): a Dual Inhibitor of CDK4 and CDK6
MOA Magnifiers
Mechanism of Action Magnifier – 2016 Desk Reference
Read More
Venetoclax (ABT-199): a Selective Inhibitor of B-Cell Lymphoma-2
MOA Magnifiers
Mechanism of Action Magnifier – 2016 Desk Reference
Read More
Ruxolitinib: a Kinase Inhibitor That Inhibits Overactive JAK Pathway Signaling
MOA Magnifiers
Mechanism of Action Magnifier – 2016 Desk Reference
Read More
Panobinostat: a Histone Deacetylase Inhibitor
MOA Magnifiers
Mechanism of Action Magnifier – 2016 Desk Reference
Read More
Idelalisib: a Selective Inhibitor of the Delta Isoform of Phosphatidylinositol 3-Kinase
MOA Magnifiers
Mechanism of Action Magnifier – 2016 Desk Reference
Read More
Ibrutinib: an Inhibitor of Bruton’s Tyrosine Kinase
MOA Magnifiers
Mechanism of Action Magnifier – 2016 Desk Reference
Read More
Duvelisib (IPI-145): a Dual Inhibitor of Phosphoinositide 3-Kinase (PI3K)-Delta and -Gamma
MOA Magnifiers
Mechanism of Action Magnifier – 2016 Desk Reference
Read More
Blinatumomab: a Bispecific CD19-Directed CD3 T-Cell Engager
MOA Magnifiers
Mechanism of Action Magnifier – 2016 Desk Reference
Read More
Dabrafenib plus Trametinib: Two Kinase Inhibitors Used in Combination to Target Different Parts of the MAPK Pathway
MOA Magnifiers
Mechanism of Action Magnifier – 2016 Desk Reference
Read More
Page 158 of 330
155
156
157
158
159
160
161
Top Trending Articles
1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
3.
Financial Toxicity in Cancer Care: Why the Conversation Must Start Before Treatment Begins
Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM, CMCA-E/M
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma